Reported 3,000,000 shares, up 1,370,000 (84.0%) from the prior quarter.
Reported value 49.2%; share count 84.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2025-12-31 | 17790000 |
| 2026-03-31 | 27555000 |
| 2026-06-30 | 29340000 |
| 2026-09-30 | 43770000 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Added | 3,000,000 | +1,370,000 (84.0%) | 1.13% | $43,770,000 | 2026-11-16 | |
| Q2 2026 | Added | 1,630,000 | +130,000 (8.7%) | 0.69% | $29,340,000 | 2026-08-14 | |
| Q1 2026 | Unchanged | 1,500,000 | 0 (0.0%) | 0.77% | $27,555,000 | 2026-05-15 | |
| Q4 2025 | New | 1,500,000 | +1,500,000 (0.0%) | 0.6% | $17,790,000 | 2026-02-17 |
Who else reported the position
118 managers reported CRESCENT BIOPHARMA INC. for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 5,904,998 | +1,771,484 | < 0.01% | $86,153,921 | 6 qtrs |
| Fairmount Funds Management LLC | Added | 3,601,316 | +853,450 | 3.3% | $52,543,200 | 6 qtrs |
| BVF INC IL | Added | 3,093,590 | +344,827 | 1.48% | $45,135,478 | 6 qtrs |
| Vestal Point Capital LP This report | Added | 3,000,000 | +1,370,000 | 1.13% | $43,770,000 | 4 qtrs |
| BlackRock Inc | Added | 2,138,232 | +866,470 | < 0.01% | $31,196,805 | 6 qtrs |
| VR Adviser LLC | Added | 2,133,734 | +158 | 1.51% | $31,131,179 | 6 qtrs |
| FCPM III SERVICES B V | Added | 2,022,679 | +344,827 | 2.78% | $29,510,887 | 4 qtrs |
| Opaleye Management Inc | Added | 1,645,984 | +326,633 | 2.71% | $24,014,907 | 4 qtrs |
| Balyasny Asset Management LLC | Reduced | 1,611,958 | -50,959 | 0.03% | $23,518,467 | 4 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 1,268,637 | +500,882 | < 0.01% | $18,509,414 | 3 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 3,000,000
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.